Gyre Therapeutics Inc GYRE
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2006-04-12 |
| Shares Out. | 91,370,000 |
| Website | gyretx.com/ ↗ |
| Phone | 18009279800 |
| Employees | 618 |
| Revenue | $22.5M |
| Gross Profit | $21.3M |
| Net Income | -$9.9M |
| Free Cash Flow | $3.1M |
| Total Assets | $162.0M |
| Total Liabilities | $25.0M |
| Equity | $137.0M |
About Gyre Therapeutics Inc
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Gyre Therapeutics Inc is a publicly traded company under the ticker symbol GYRE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)